类风湿关节炎TNF抑制剂按疾病活动度减量的3年结局:DRESS研究
基于DRESS随机对照实用性非劣效策略试验的3年数据,评估按疾病活动度指导的TNF抑制剂减量(DR)与常规治疗(UC)在类风湿关节炎中的长期结局。结果显示两组主要复发、疾病活动度、功能、生活质量及影像学进展均保持稳定且无显著差异,DR组TNFi用量持续较低,但未带来其他额外获益。
要点
- 按疾病活动度指导的TNFi减量在3年内维持疗效与安全性,主要复发累积发生率组间差异无统计学意义。
- DR组TNFi用量持续较低,UC组在延长期用量下降,但未观察到其他额外获益。
- 短期复发在DR组更常见(0至36个月累积发生率83%对44%),但疾病活动度、功能与影像学结局稳定。
核心结论
- 在类风湿关节炎中,按疾病活动度指导的TNFi减量在3年内维持安全性和疗效,TNFi用量大幅减少,但无其他额外获益。
- 实施减量策略可大幅改善TNFi的成本效益使用。
研究设计与样本
- DRESS研究为随机对照实用性非劣效策略试验(荷兰试验注册号NTR 3216),干预阶段(第0至18个月)患者随机分为减量组(DR)或常规治疗组(UC)。
- 延长期(第18至36个月)两组治疗策略趋同,均继续按方案严密控制并允许剂量优化,纳入延长期的180例中有172例。
- 采用意向性治疗分析,评估复发、DAS28-CRP、HAQ-DI、EQ5D-5L、用药、影像学进展(SvdH评分)及不良事件。
主要发现
- 延长期主要复发累积发生率DR组10%、UC组12%(差值-2%,95%CI -8至15),0至36个月分别为17%和14%(差值3%,95%CI -9至13)。
- 延长期短期复发累积发生率DR组43%(33至52%)、UC组35%(23至49%),0至36个月分别为83%(75至90%)和44%(31至58%)。
- 平均DAS28-CRP、HAQ-DI、EQ5D-5L和SvdH评分保持稳定且组间无显著差异,TNFi用量DR组持续较低、UC组下降,不良事件累积发生率组间无显著差异。
关键数值与推荐
- 主要复发累积发生率:延长期DR组10%对UC组12%(差值-2%,95%CI -8至15);0至36个月DR组17%对UC组14%(差值3%,95%CI -9至13)。
- 短期复发累积发生率:延长期DR组43%(33至52%)对UC组35%(23至49%);0至36个月DR组83%(75至90%)对UC组44%(31至58%)。
临床怎么用
- 对达到稳定控制的类风湿关节炎患者,可按疾病活动度指导逐步减量TNFi,并继续严密监测以维持疗效。
- 减量可大幅降低TNFi用量与成本,但应告知患者短期复发在减量组更常见,需加强随访。
局限性
- 延长期两组治疗策略趋同并允许剂量优化,可能影响组间长期比较的解释。
- 摘要未报告盲法、样本量计算细节及主要终点非劣效界值等信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Tumour necrosis factor inhibitors (TNFi) are effective in rheumatoid arthritis (RA), but disadvantages include adverse events (AEs) and high costs. This can be improved by disease activity-guided dose reduction (DR). We aimed to assess long-term outcomes of TNFi DR in RA by using 3-year data from the DRESS study (Dose REduction Strategy of Subcutaneous TNF inhibitors study). METHODS: In the intervention phase (month 0-18) of the DRESS study (Dutch trial register, NTR 3216), patients were randomised to DR or usual care (UC). In the extension phase (month 18-36), treatment strategies in both groups converged to continuation of protocolised tight control and allowed dose optimisation. Intention-to-treat analyses were done on flare, disease activity (28 joint count-based disease activity score with C reactive protein (DAS28-CRP)), functioning (health assessment questionnaire-disability index (HAQ-DI)), quality of life (Euroqol 5 dimensions 5 levels questionnaire (EQ5D-5L)), medication use, radiographic progression (Sharp van der Heijde score (SvdH)) and AE. RESULTS: 172/180 patients included in the DRESS study were included in the extension phase. Cumulative incidences of major flare were 10% and 12% (-2%, 95% CI -8 to 15) in DR and UC groups in the extension phase, and 17% and 14% (3%, 95% CI -9 to 13) from 0 to 36 months. Cumulative incidences of short-lived flares were 43% (33 to 52%)%) and 35% (23 to 49%)%) in DR and UC groups in the extension phase, and 83% (75 to 90%)%) and 44% (31 to 58%)%) from 0 to 36 months. Mean DAS28-CRP, HAQ-DI, EQ5D-5L and SvdH remained stable and not significantly different between groups. TNFi use remained low in the DR group and decreased in the UC group. Cumulative incidences of AE were not significantly different between groups. CONCLUSIONS: Safety and efficacy of disease activity guided TNFi DR in RA are maintained up to 3 years, with a large reduction in TNFi use, but no other benefits. Implementation of DR would vastly improve the cost-effective use of TNFi.
引用
- Bouman CA, van Herwaarden N, van den Hoogen FH, et al. Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial. Ann Rheum Dis. 2017. PMID: 28606961. doi:10.1136/annrheumdis-2017-211169
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。